Global Duchenne Muscular Dystrophy Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Duchenne Muscular Dystrophy market size is predicted to grow from US$ 2218 million in 2025 to US$ 19500 million in 2031; it is expected to grow at a CAGR of 43.7% from 2025 to 2031.
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
LP Information, Inc. (LPI) ' newest research report, the “Duchenne Muscular Dystrophy Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy sales in 2024, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy sales for 2025 through 2031. With Duchenne Muscular Dystrophy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy industry.
This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy.
This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Duchenne Muscular Dystrophy market?
What factors are driving Duchenne Muscular Dystrophy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Duchenne Muscular Dystrophy market opportunities vary by end market size?
How does Duchenne Muscular Dystrophy break out by Type, by Application?
The global Duchenne Muscular Dystrophy market size is predicted to grow from US$ 2218 million in 2025 to US$ 19500 million in 2031; it is expected to grow at a CAGR of 43.7% from 2025 to 2031.
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
LP Information, Inc. (LPI) ' newest research report, the “Duchenne Muscular Dystrophy Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy sales in 2024, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy sales for 2025 through 2031. With Duchenne Muscular Dystrophy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy industry.
This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy.
This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Exondys 51
- Emflaza
- Translarna
- Hospitals
- Clinics
- Home Care
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
What is the 10-year outlook for the global Duchenne Muscular Dystrophy market?
What factors are driving Duchenne Muscular Dystrophy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Duchenne Muscular Dystrophy market opportunities vary by end market size?
How does Duchenne Muscular Dystrophy break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Duchenne Muscular Dystrophy by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Duchenne Muscular Dystrophy by Country/Region, 2020, 2024 & 2031
2.2 Duchenne Muscular Dystrophy Segment by Type
2.2.1 Exondys
2.2.2 Emflaza
2.2.3 Translarna
2.3 Duchenne Muscular Dystrophy Sales by Type
2.3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)
2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2020-2025)
2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2020-2025)
2.4 Duchenne Muscular Dystrophy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy Sales by Application
2.5.1 Global Duchenne Muscular Dystrophy Sale Market Share by Application (2020-2025)
2.5.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Application (2020-2025)
2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Duchenne Muscular Dystrophy Breakdown Data by Company
3.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Company (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2025)
3.2 Global Duchenne Muscular Dystrophy Annual Revenue by Company (2020-2025)
3.2.1 Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025)
3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)
3.3 Global Duchenne Muscular Dystrophy Sale Price by Company
3.4 Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Duchenne Muscular Dystrophy Product Location Distribution
3.4.2 Players Duchenne Muscular Dystrophy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DUCHENNE MUSCULAR DYSTROPHY BY GEOGRAPHIC REGION
4.1 World Historic Duchenne Muscular Dystrophy Market Size by Geographic Region (2020-2025)
4.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Duchenne Muscular Dystrophy Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Duchenne Muscular Dystrophy Market Size by Country/Region (2020-2025)
4.2.1 Global Duchenne Muscular Dystrophy Annual Sales by Country/Region (2020-2025)
4.2.2 Global Duchenne Muscular Dystrophy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Duchenne Muscular Dystrophy Sales Growth
4.4 APAC Duchenne Muscular Dystrophy Sales Growth
4.5 Europe Duchenne Muscular Dystrophy Sales Growth
4.6 Middle East & Africa Duchenne Muscular Dystrophy Sales Growth
5 AMERICAS
5.1 Americas Duchenne Muscular Dystrophy Sales by Country
5.1.1 Americas Duchenne Muscular Dystrophy Sales by Country (2020-2025)
5.1.2 Americas Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
5.2 Americas Duchenne Muscular Dystrophy Sales by Type (2020-2025)
5.3 Americas Duchenne Muscular Dystrophy Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Sales by Region
6.1.1 APAC Duchenne Muscular Dystrophy Sales by Region (2020-2025)
6.1.2 APAC Duchenne Muscular Dystrophy Revenue by Region (2020-2025)
6.2 APAC Duchenne Muscular Dystrophy Sales by Type (2020-2025)
6.3 APAC Duchenne Muscular Dystrophy Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Duchenne Muscular Dystrophy by Country
7.1.1 Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025)
7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
7.2 Europe Duchenne Muscular Dystrophy Sales by Type (2020-2025)
7.3 Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Duchenne Muscular Dystrophy by Country
8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025)
8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Sales by Type (2020-2025)
8.3 Middle East & Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy
10.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy
10.4 Industry Chain Structure of Duchenne Muscular Dystrophy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Duchenne Muscular Dystrophy Distributors
11.3 Duchenne Muscular Dystrophy Customer
12 WORLD FORECAST REVIEW FOR DUCHENNE MUSCULAR DYSTROPHY BY GEOGRAPHIC REGION
12.1 Global Duchenne Muscular Dystrophy Market Size Forecast by Region
12.1.1 Global Duchenne Muscular Dystrophy Forecast by Region (2026-2031)
12.1.2 Global Duchenne Muscular Dystrophy Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Duchenne Muscular Dystrophy Forecast by Type (2026-2031)
12.7 Global Duchenne Muscular Dystrophy Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Sarepta Therapeutics
13.1.1 Sarepta Therapeutics Company Information
13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sarepta Therapeutics Main Business Overview
13.1.5 Sarepta Therapeutics Latest Developments
13.2 PTC Therapeutics
13.2.1 PTC Therapeutics Company Information
13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 PTC Therapeutics Main Business Overview
13.2.5 PTC Therapeutics Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Italfarmaco
13.5.1 Italfarmaco Company Information
13.5.2 Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Italfarmaco Main Business Overview
13.5.5 Italfarmaco Latest Developments
13.6 Santhera Pharmaceuticals
13.6.1 Santhera Pharmaceuticals Company Information
13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Santhera Pharmaceuticals Main Business Overview
13.6.5 Santhera Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Duchenne Muscular Dystrophy Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Duchenne Muscular Dystrophy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Exondys 51
Table 4. Major Players of Emflaza
Table 5. Major Players ofTranslarna
Table 6. Global Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 7. Global Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Table 8. Global Duchenne Muscular Dystrophy Revenue byType (2020-2025) & ($ million)
Table 9. Global Duchenne Muscular Dystrophy Revenue Market Share byType (2020-2025)
Table 10. Global Duchenne Muscular Dystrophy Sale Price byType (2020-2025) & (USD/Dose)
Table 11. Global Duchenne Muscular Dystrophy Sale by Application (2020-2025) & (K Doses)
Table 12. Global Duchenne Muscular Dystrophy Sale Market Share by Application (2020-2025)
Table 13. Global Duchenne Muscular Dystrophy Revenue by Application (2020-2025) & ($ million)
Table 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2020-2025)
Table 15. Global Duchenne Muscular Dystrophy Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global Duchenne Muscular Dystrophy Sales by Company (2020-2025) & (K Doses)
Table 17. Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2025)
Table 18. Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)
Table 20. Global Duchenne Muscular Dystrophy Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution and Sales Area
Table 22. Players Duchenne Muscular Dystrophy Products Offered
Table 23. Duchenne Muscular Dystrophy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Duchenne Muscular Dystrophy Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global Duchenne Muscular Dystrophy Sales Market Share Geographic Region (2020-2025)
Table 28. Global Duchenne Muscular Dystrophy Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Duchenne Muscular Dystrophy Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2020-2025)
Table 32. Global Duchenne Muscular Dystrophy Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Duchenne Muscular Dystrophy Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 35. Americas Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2025)
Table 36. Americas Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 38. Americas Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 39. APAC Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)
Table 40. APAC Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2025)
Table 41. APAC Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 43. APAC Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 44. Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 45. Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 47. Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 51. Middle East & Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy
Table 53. Key Market Challenges & Risks of Duchenne Muscular Dystrophy
Table 54. Key IndustryTrends of Duchenne Muscular Dystrophy
Table 55. Duchenne Muscular Dystrophy Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Duchenne Muscular Dystrophy Distributors List
Table 58. Duchenne Muscular Dystrophy Customer List
Table 59. Global Duchenne Muscular Dystrophy SalesForecast by Region (2026-2031) & (K Doses)
Table 60. Global Duchenne Muscular Dystrophy RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)
Table 62. Americas Duchenne Muscular Dystrophy Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Duchenne Muscular Dystrophy SalesForecast by Region (2026-2031) & (K Doses)
Table 64. APAC Duchenne Muscular Dystrophy Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)
Table 66. Europe Duchenne Muscular Dystrophy RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa Duchenne Muscular Dystrophy RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Duchenne Muscular Dystrophy SalesForecast byType (2026-2031) & (K Doses)
Table 70. Global Duchenne Muscular Dystrophy RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Duchenne Muscular Dystrophy SalesForecast by Application (2026-2031) & (K Doses)
Table 72. Global Duchenne Muscular Dystrophy RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. SareptaTherapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 74. SareptaTherapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 75. SareptaTherapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. SareptaTherapeutics Main Business
Table 77. SareptaTherapeutics Latest Developments
Table 78. PTCTherapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 79. PTCTherapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 80. PTCTherapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. PTCTherapeutics Main Business
Table 82. PTCTherapeutics Latest Developments
Table 83. Pfizer Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 84. Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 85. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Pfizer Main Business
Table 87. Pfizer Latest Developments
Table 88. Bristol-Myers Squibb Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 89. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 90. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Bristol-Myers Squibb Main Business
Table 92. Bristol-Myers Squibb Latest Developments
Table 93. Italfarmaco Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 94. Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 95. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Italfarmaco Main Business
Table 97. Italfarmaco Latest Developments
Table 98. Santhera Pharmaceuticals Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 99. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 100. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Santhera Pharmaceuticals Main Business
Table 102. Santhera Pharmaceuticals Latest Developments
LIST OFFIGURES
Figure 1. Picture of Duchenne Muscular Dystrophy
Figure 2. Duchenne Muscular Dystrophy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Duchenne Muscular Dystrophy Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Duchenne Muscular Dystrophy Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Duchenne Muscular Dystrophy Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2024)
Figure 10. Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Exondys 51
Figure 12. Product Picture of Emflaza
Figure 13. Product Picture ofTranslarna
Figure 14. Global Duchenne Muscular Dystrophy Sales Market Share byType in 2025
Figure 15. Global Duchenne Muscular Dystrophy Revenue Market Share byType (2020-2025)
Figure 16. Duchenne Muscular Dystrophy Consumed in Hospitals
Figure 17. Global Duchenne Muscular Dystrophy Market: Hospitals (2020-2025) & (K Doses)
Figure 18. Duchenne Muscular Dystrophy Consumed in Clinics
Figure 19. Global Duchenne Muscular Dystrophy Market: Clinics (2020-2025) & (K Doses)
Figure 20. Duchenne Muscular Dystrophy Consumed in Home Care
Figure 21. Global Duchenne Muscular Dystrophy Market: Home Care (2020-2025) & (K Doses)
Figure 22. Global Duchenne Muscular Dystrophy Sale Market Share by Application (2024)
Figure 23. Global Duchenne Muscular Dystrophy Revenue Market Share by Application in 2025
Figure 24. Duchenne Muscular Dystrophy Sales by Company in 2025 (K Doses)
Figure 25. Global Duchenne Muscular Dystrophy Sales Market Share by Company in 2025
Figure 26. Duchenne Muscular Dystrophy Revenue by Company in 2025 ($ millions)
Figure 27. Global Duchenne Muscular Dystrophy Revenue Market Share by Company in 2025
Figure 28. Global Duchenne Muscular Dystrophy Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 31. Americas Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 32. APAC Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 33. APAC Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 34. Europe Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 35. Europe Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 37. Middle East & Africa Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 38. Americas Duchenne Muscular Dystrophy Sales Market Share by Country in 2025
Figure 39. Americas Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
Figure 40. Americas Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 41. Americas Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 42. United States Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Duchenne Muscular Dystrophy Sales Market Share by Region in 2025
Figure 47. APAC Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2025)
Figure 48. APAC Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 49. APAC Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 50. China Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 54. India Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 56. ChinaTaiwan Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Duchenne Muscular Dystrophy Sales Market Share by Country in 2025
Figure 58. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
Figure 59. Europe Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 60. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 61. Germany Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 62.France Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 68. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 69. Egypt Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 72.Turkey Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy in 2025
Figure 75. Manufacturing Process Analysis of Duchenne Muscular Dystrophy
Figure 76. Industry Chain Structure of Duchenne Muscular Dystrophy
Figure 77. Channels of Distribution
Figure 78. Global Duchenne Muscular Dystrophy Sales MarketForecast by Region (2026-2031)
Figure 79. Global Duchenne Muscular Dystrophy Revenue Market ShareForecast by Region (2026-2031)
Figure 80. Global Duchenne Muscular Dystrophy Sales Market ShareForecast byType (2026-2031)
Figure 81. Global Duchenne Muscular Dystrophy Revenue Market ShareForecast byType (2026-2031)
Figure 82. Global Duchenne Muscular Dystrophy Sales Market ShareForecast by Application (2026-2031)
Figure 83. Global Duchenne Muscular Dystrophy Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Duchenne Muscular Dystrophy by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Duchenne Muscular Dystrophy by Country/Region, 2020, 2024 & 2031
2.2 Duchenne Muscular Dystrophy Segment by Type
2.2.1 Exondys
2.2.2 Emflaza
2.2.3 Translarna
2.3 Duchenne Muscular Dystrophy Sales by Type
2.3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)
2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2020-2025)
2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2020-2025)
2.4 Duchenne Muscular Dystrophy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy Sales by Application
2.5.1 Global Duchenne Muscular Dystrophy Sale Market Share by Application (2020-2025)
2.5.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Application (2020-2025)
2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Duchenne Muscular Dystrophy Breakdown Data by Company
3.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Company (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2025)
3.2 Global Duchenne Muscular Dystrophy Annual Revenue by Company (2020-2025)
3.2.1 Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025)
3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)
3.3 Global Duchenne Muscular Dystrophy Sale Price by Company
3.4 Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Duchenne Muscular Dystrophy Product Location Distribution
3.4.2 Players Duchenne Muscular Dystrophy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DUCHENNE MUSCULAR DYSTROPHY BY GEOGRAPHIC REGION
4.1 World Historic Duchenne Muscular Dystrophy Market Size by Geographic Region (2020-2025)
4.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Duchenne Muscular Dystrophy Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Duchenne Muscular Dystrophy Market Size by Country/Region (2020-2025)
4.2.1 Global Duchenne Muscular Dystrophy Annual Sales by Country/Region (2020-2025)
4.2.2 Global Duchenne Muscular Dystrophy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Duchenne Muscular Dystrophy Sales Growth
4.4 APAC Duchenne Muscular Dystrophy Sales Growth
4.5 Europe Duchenne Muscular Dystrophy Sales Growth
4.6 Middle East & Africa Duchenne Muscular Dystrophy Sales Growth
5 AMERICAS
5.1 Americas Duchenne Muscular Dystrophy Sales by Country
5.1.1 Americas Duchenne Muscular Dystrophy Sales by Country (2020-2025)
5.1.2 Americas Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
5.2 Americas Duchenne Muscular Dystrophy Sales by Type (2020-2025)
5.3 Americas Duchenne Muscular Dystrophy Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Sales by Region
6.1.1 APAC Duchenne Muscular Dystrophy Sales by Region (2020-2025)
6.1.2 APAC Duchenne Muscular Dystrophy Revenue by Region (2020-2025)
6.2 APAC Duchenne Muscular Dystrophy Sales by Type (2020-2025)
6.3 APAC Duchenne Muscular Dystrophy Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Duchenne Muscular Dystrophy by Country
7.1.1 Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025)
7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
7.2 Europe Duchenne Muscular Dystrophy Sales by Type (2020-2025)
7.3 Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Duchenne Muscular Dystrophy by Country
8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025)
8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Sales by Type (2020-2025)
8.3 Middle East & Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy
10.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy
10.4 Industry Chain Structure of Duchenne Muscular Dystrophy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Duchenne Muscular Dystrophy Distributors
11.3 Duchenne Muscular Dystrophy Customer
12 WORLD FORECAST REVIEW FOR DUCHENNE MUSCULAR DYSTROPHY BY GEOGRAPHIC REGION
12.1 Global Duchenne Muscular Dystrophy Market Size Forecast by Region
12.1.1 Global Duchenne Muscular Dystrophy Forecast by Region (2026-2031)
12.1.2 Global Duchenne Muscular Dystrophy Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Duchenne Muscular Dystrophy Forecast by Type (2026-2031)
12.7 Global Duchenne Muscular Dystrophy Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Sarepta Therapeutics
13.1.1 Sarepta Therapeutics Company Information
13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sarepta Therapeutics Main Business Overview
13.1.5 Sarepta Therapeutics Latest Developments
13.2 PTC Therapeutics
13.2.1 PTC Therapeutics Company Information
13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 PTC Therapeutics Main Business Overview
13.2.5 PTC Therapeutics Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Italfarmaco
13.5.1 Italfarmaco Company Information
13.5.2 Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Italfarmaco Main Business Overview
13.5.5 Italfarmaco Latest Developments
13.6 Santhera Pharmaceuticals
13.6.1 Santhera Pharmaceuticals Company Information
13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Santhera Pharmaceuticals Main Business Overview
13.6.5 Santhera Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Duchenne Muscular Dystrophy Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Duchenne Muscular Dystrophy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Exondys 51
Table 4. Major Players of Emflaza
Table 5. Major Players ofTranslarna
Table 6. Global Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 7. Global Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Table 8. Global Duchenne Muscular Dystrophy Revenue byType (2020-2025) & ($ million)
Table 9. Global Duchenne Muscular Dystrophy Revenue Market Share byType (2020-2025)
Table 10. Global Duchenne Muscular Dystrophy Sale Price byType (2020-2025) & (USD/Dose)
Table 11. Global Duchenne Muscular Dystrophy Sale by Application (2020-2025) & (K Doses)
Table 12. Global Duchenne Muscular Dystrophy Sale Market Share by Application (2020-2025)
Table 13. Global Duchenne Muscular Dystrophy Revenue by Application (2020-2025) & ($ million)
Table 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2020-2025)
Table 15. Global Duchenne Muscular Dystrophy Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global Duchenne Muscular Dystrophy Sales by Company (2020-2025) & (K Doses)
Table 17. Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2025)
Table 18. Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)
Table 20. Global Duchenne Muscular Dystrophy Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution and Sales Area
Table 22. Players Duchenne Muscular Dystrophy Products Offered
Table 23. Duchenne Muscular Dystrophy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Duchenne Muscular Dystrophy Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global Duchenne Muscular Dystrophy Sales Market Share Geographic Region (2020-2025)
Table 28. Global Duchenne Muscular Dystrophy Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Duchenne Muscular Dystrophy Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2020-2025)
Table 32. Global Duchenne Muscular Dystrophy Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Duchenne Muscular Dystrophy Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 35. Americas Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2025)
Table 36. Americas Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 38. Americas Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 39. APAC Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)
Table 40. APAC Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2025)
Table 41. APAC Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 43. APAC Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 44. Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 45. Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 47. Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)
Table 51. Middle East & Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy
Table 53. Key Market Challenges & Risks of Duchenne Muscular Dystrophy
Table 54. Key IndustryTrends of Duchenne Muscular Dystrophy
Table 55. Duchenne Muscular Dystrophy Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Duchenne Muscular Dystrophy Distributors List
Table 58. Duchenne Muscular Dystrophy Customer List
Table 59. Global Duchenne Muscular Dystrophy SalesForecast by Region (2026-2031) & (K Doses)
Table 60. Global Duchenne Muscular Dystrophy RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)
Table 62. Americas Duchenne Muscular Dystrophy Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Duchenne Muscular Dystrophy SalesForecast by Region (2026-2031) & (K Doses)
Table 64. APAC Duchenne Muscular Dystrophy Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)
Table 66. Europe Duchenne Muscular Dystrophy RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa Duchenne Muscular Dystrophy RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Duchenne Muscular Dystrophy SalesForecast byType (2026-2031) & (K Doses)
Table 70. Global Duchenne Muscular Dystrophy RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Duchenne Muscular Dystrophy SalesForecast by Application (2026-2031) & (K Doses)
Table 72. Global Duchenne Muscular Dystrophy RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. SareptaTherapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 74. SareptaTherapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 75. SareptaTherapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. SareptaTherapeutics Main Business
Table 77. SareptaTherapeutics Latest Developments
Table 78. PTCTherapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 79. PTCTherapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 80. PTCTherapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. PTCTherapeutics Main Business
Table 82. PTCTherapeutics Latest Developments
Table 83. Pfizer Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 84. Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 85. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Pfizer Main Business
Table 87. Pfizer Latest Developments
Table 88. Bristol-Myers Squibb Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 89. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 90. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Bristol-Myers Squibb Main Business
Table 92. Bristol-Myers Squibb Latest Developments
Table 93. Italfarmaco Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 94. Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 95. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Italfarmaco Main Business
Table 97. Italfarmaco Latest Developments
Table 98. Santhera Pharmaceuticals Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 99. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 100. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Santhera Pharmaceuticals Main Business
Table 102. Santhera Pharmaceuticals Latest Developments
LIST OFFIGURES
Figure 1. Picture of Duchenne Muscular Dystrophy
Figure 2. Duchenne Muscular Dystrophy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Duchenne Muscular Dystrophy Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Duchenne Muscular Dystrophy Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Duchenne Muscular Dystrophy Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2024)
Figure 10. Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Exondys 51
Figure 12. Product Picture of Emflaza
Figure 13. Product Picture ofTranslarna
Figure 14. Global Duchenne Muscular Dystrophy Sales Market Share byType in 2025
Figure 15. Global Duchenne Muscular Dystrophy Revenue Market Share byType (2020-2025)
Figure 16. Duchenne Muscular Dystrophy Consumed in Hospitals
Figure 17. Global Duchenne Muscular Dystrophy Market: Hospitals (2020-2025) & (K Doses)
Figure 18. Duchenne Muscular Dystrophy Consumed in Clinics
Figure 19. Global Duchenne Muscular Dystrophy Market: Clinics (2020-2025) & (K Doses)
Figure 20. Duchenne Muscular Dystrophy Consumed in Home Care
Figure 21. Global Duchenne Muscular Dystrophy Market: Home Care (2020-2025) & (K Doses)
Figure 22. Global Duchenne Muscular Dystrophy Sale Market Share by Application (2024)
Figure 23. Global Duchenne Muscular Dystrophy Revenue Market Share by Application in 2025
Figure 24. Duchenne Muscular Dystrophy Sales by Company in 2025 (K Doses)
Figure 25. Global Duchenne Muscular Dystrophy Sales Market Share by Company in 2025
Figure 26. Duchenne Muscular Dystrophy Revenue by Company in 2025 ($ millions)
Figure 27. Global Duchenne Muscular Dystrophy Revenue Market Share by Company in 2025
Figure 28. Global Duchenne Muscular Dystrophy Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 31. Americas Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 32. APAC Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 33. APAC Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 34. Europe Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 35. Europe Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
Figure 37. Middle East & Africa Duchenne Muscular Dystrophy Revenue 2020-2025 ($ millions)
Figure 38. Americas Duchenne Muscular Dystrophy Sales Market Share by Country in 2025
Figure 39. Americas Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
Figure 40. Americas Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 41. Americas Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 42. United States Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Duchenne Muscular Dystrophy Sales Market Share by Region in 2025
Figure 47. APAC Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2025)
Figure 48. APAC Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 49. APAC Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 50. China Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 54. India Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 56. ChinaTaiwan Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Duchenne Muscular Dystrophy Sales Market Share by Country in 2025
Figure 58. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
Figure 59. Europe Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 60. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 61. Germany Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 62.France Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)
Figure 68. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Figure 69. Egypt Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 72.Turkey Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Duchenne Muscular Dystrophy Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy in 2025
Figure 75. Manufacturing Process Analysis of Duchenne Muscular Dystrophy
Figure 76. Industry Chain Structure of Duchenne Muscular Dystrophy
Figure 77. Channels of Distribution
Figure 78. Global Duchenne Muscular Dystrophy Sales MarketForecast by Region (2026-2031)
Figure 79. Global Duchenne Muscular Dystrophy Revenue Market ShareForecast by Region (2026-2031)
Figure 80. Global Duchenne Muscular Dystrophy Sales Market ShareForecast byType (2026-2031)
Figure 81. Global Duchenne Muscular Dystrophy Revenue Market ShareForecast byType (2026-2031)
Figure 82. Global Duchenne Muscular Dystrophy Sales Market ShareForecast by Application (2026-2031)
Figure 83. Global Duchenne Muscular Dystrophy Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
January 2025
91 pages
Global Duchenne Muscular Dystrophy Market 2026 by Company, Regions, Type and Application, Forecast to 2032
US$ 3,480.00
June 2026
84 pages
Asia-Pacific Duchenne Muscular Dystrophy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
US$ 4,480.00
May 2018
104 pages
